Variable | Category | n | % |
|---|
Study Category | Drug | 2152 | 56% |
Medical Device | 1265 | 33% |
No product | 351 | 9% |
Therapies | 100 | 3% |
Genetic | 1 | 0% |
Study Location in Israel | CENTER | 2051 | 53% |
NORTH | 857 | 22% |
TLV | 498 | 13% |
JERUSALEM | 297 | 8% |
SOUTH | 144 | 4% |
ASHKELON | 46 | 1% |
NIH Register | No | 2364 | 61% |
Yes | 1532 | 39% |
Randomization | No | 1917 | 49% |
Yes | 1979 | 51% |
Blindness | No | 2523 | 65% |
Double-blind | 1161 | 30% |
Single blind | 212 | 5% |
Registered Product | Not registered | 1843 | 47% |
Israel + International | 1341 | 34% |
Israel | 426 | 11% |
International | 286 | 7% |
Recruitment Status | Recruitment not begun | 2174 | 56% |
Recruit | 998 | 26% |
End Study | 398 | 10% |
End Recruit | 324 | 8% |
Approval year | 2011 | 12 | 0% |
2012 | 7 | 0% |
2013 | 10 | 0% |
2014 | 45 | 1% |
2015 | 87 | 2% |
2016 | 166 | 4% |
2017 | 511 | 13% |
2018 | 566 | 15% |
2019 | 597 | 15% |
2020 | 733 | 19% |
2021 | 700 | 18% |
2022 | 462 | 12% |
Total | | 3896 | 100% |
- Out of the 3,896 studies analyzed, the majority belong to the “Drug” category (56%), followed by “Medical Device” (33%). There are also studies categorized as “No product” (9%), “Therapies” (3%), and no studies classified as “Genetic”. In terms of geographical distribution within Israel, a significant portion of the studies (53%) are concentrated in the central region. Other regions that have conducted studies include the north (22%), Tel Aviv area (13%), Jerusalem (8%), southern region (4%) and Ashkelon (1%)
- Regarding registration, 39% of these studies are registered both in MyTrial and the NIH registry platform. Blinding methods were found to vary across these trials - around 65% were conducted without any blinding procedures in place; however, approximately 30% used double-blind techniques, and 5% employed single-blind approaches
- Product registration status varies as well, with 47% featuring unregistered products, 34% of the trials involving products registered both in Israel and internationally, 11% exclusively in Israel, and 7% solely internationally. Recruitment statuses indicate that 56% of studies have not yet initiated recruitment, while 26% are actively recruiting participants. The rest, either have concluded (10%) or completed recruitment (8%)
- There is an increasing trend in the distribution of study approval years from 2015 onwards. The highest proportions are seen in 2020 (19%) and 2021 (18%). In contrast, the years 2011 to 2014 each have no studies accounted for
